See also Monoclonal antibodies

General information

Basiliximab is a chimeric (human/mouse) anti-interleukin-2 receptor monoclonal antibody used in the prophylaxis of acute renal transplant rejection. It acts by binding the alpha chain of interleukin-2 receptors on activated T lymphocytes. Initially positive results in phase III trials have not been generally confirmed [ , ]. Compared with placebo, basiliximab was not associated with any specific adverse effects in early studies [ ]. However, severe hypersensitivity reactions can occur and can be associated with the cytokine release syndrome.

Organs and systems

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here